Opinion|Videos|February 26, 2024
Ongoing Research on Neoadjuvant Therapies in Muscle-Invasive Bladder Cancer
Focusing on neoadjuvant therapy, the expert panel discusses ongoing clinical research in muscle-invasive bladder cancer and the potential role of novel strategies in the treatment space.
Advertisement
Episodes in this series
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval of Daraxonrasib in Pancreatic Cancer
2
Time-Limited Pirtobrutinib-Based Triplet Yields High Rates of Undetectable MRD in First-Line CLL
3
SERENA-4 Misses Primary PFS End Point With Camizestrant Plus Palbociclib in First-Line ER+ Advanced Breast Cancer
4
Anselamimab Misses Overall Primary End Point but Reduces Mortality in Kappa AL Amyloidosis
5